Disseminated gonococcal infection in a patient with paroxysmal nocturnal hemoglobinuria having received ravulizumab and meningococcal vaccine
Main Authors: | Zhi-Ye Yu, Ming-Jui Tsai, Yu-Jen Lin, Wang-Da Liu, Sheng-Chieh Chou, Chien-Ching Hung |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-08-01
|
Series: | Journal of Microbiology, Immunology and Infection |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1684118220301547 |
Similar Items
-
No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab.
by: Ferras Alashkar, et al.
Published: (2020-01-01) -
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
by: Robert M. Stern, et al.
Published: (2019-09-01) -
Gonococcal infection in mice : microbial and host factors related to infection
by: Streeter, Philip Reel
Published: (2011) -
Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria
by: Carolyn E. Schwartz, et al.
Published: (2021-09-01) -
Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report
by: Wolfgang Füreder, et al.
Published: (2020-08-01)